This article exists as part of the online archive for HuffPost Canada, which closed in 2021.

Turing reneges on cutting $750-a-pill drug's price, rival's new 99-cent version selling well

TRENTON, N.J. — After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine's price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.

Instead, the small biotech company says it's reducing the price for hospitals by up to 50 per cent for its Daraprim, which treats a rare parasitic infection that mainly strikes pregnant women and HIV patients.

The 62-year-old drug had no competition until a furor over the gigantic price hike erupted, triggering multiple government investigations.

Then a pharmacy that compounds prescription drugs for individual patients stepped in and started selling a capsule version for 99 cents. Imprimis Pharmaceuticals says orders are pouring in from doctors and it says it has dispensed more than 2,500 capsules in barely a month.

Linda A. Johnson, The Associated Press

Suggest a correction
This article exists as part of the online archive for HuffPost Canada. Certain site features have been disabled. If you have questions or concerns, please check our FAQ or contact support@huffpost.com.